Skip to main content
BioCentury on BioBusiness
Feature Story

Zarxio lessons

What Sandoz's Mark McCamish thinks are the take-homes from the Zarxio adcomm

By Steve Usdin, Washington Editor

Sandoz is blazing a trail for commercialization of biosimilars in the U.S. with its application to market Zarxio, a biosimilar version of Amgen Inc.'s Neupogen filgrastim. The Novartis AG unit is using its first-mover position to force FDA and the courts to make decisions that will shape the economic and regulatory landscape for biosimilars.

BioCentury recently spoke with Mark McCamish, global head of biopharmaceuticals and oncology injectables development at Sandoz.

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial